Advertisement

Topics

Elitek (Rasburicase) Immuno-Monitoring Study

2014-08-27 03:14:50 | BioPortfolio

Summary

Primary Objective:

To determine the incidence, titer and type of anti-rasburicase antibodies in the context of hypersensitivity reaction(s) or the loss of uricolytic activity occurring in patients with relapsed leukemia/lymphoma who have been re-treated with rasburicase and have experienced a hypersensitivity reaction or loss of uricolytic activity.

Study Design

Observational Model: Cohort, Time Perspective: Prospective

Conditions

Tumor Lysis Syndrome

Location

Sanofi-Aventis Administrative Office
Bridgewater
New Jersey
United States

Status

Recruiting

Source

Sanofi-Aventis

Results (where available)

View Results

Links

Published on BioPortfolio: 2014-08-27T03:14:50-0400

Clinical Trials [905 Associated Clinical Trials listed on BioPortfolio]

Fasturtec TLS Treatment / Prophylysis

An open-label study to determine the efficacy and safety of Rasburicase used for the prevention and treatment of tumor lysis syndrome

Febuxostat for Tumor Lysis Syndrome Prevention in Hematological Malignancies of Paediatric Patients and Adults

The purpose of this study is to compare the exposure of febuxostat in pediatric patients (≥6

Rasburicase in Patients at Risk for Tumor Lysis Syndrome

Primary Objectives: To determine the efficacy of rasburicase administered as a single dose followed by as needed dosing (investigational arm) as compared to fixed dosing for 5 days (stand...

Maternal Outcomes Following Manual Lysis of the Placenta.

Comparison of maternal outcomes following manual lysis of placenta 15 vs 30 minutes after delivery. A primary outcome of the drop in hemoglobin will be compared between the two groups. Sec...

Rasburicase in Tumor Lysis Syndrome

The purpose of this study is to determine whether rasburicase is effective and safety in correcting hyperuricemia.

PubMed Articles [10846 Associated PubMed Articles listed on BioPortfolio]

Tumor Lysis Syndrome after Bilobectomy for Typical Carcinoid Tumor of the Lung.

Tumor lysis syndrome (TLS) is a life-threatening complication comprised of hyperuricemia, hyperkalemia, hyperphosphatemia, and hypocalcemia attributed to release of intracellular contents. While tradi...

Revised Dose Ramp-Up to Mitigate the Risk of Tumor Lysis Syndrome When Initiating Venetoclax in Patients With Mantle Cell Lymphoma.

Aurovertin B sensitizes colorectal cancer cells to NK cell recognition and lysis.

The natural killer group 2D (NKG2D) receptor on natural killer (NK) cells play an important role in immunosurveillance to cancer cells, which could mediate the eradication of tumor cells through speci...

Wilms Tumor after Orthotopic Liver Transplant in a Patient with Alagille Syndrome.

We present a case of Wilms Tumor in a patient with Alagille syndrome ten months after liver transplant. We explore a suggested genetic connection between these two diseases. In children with Wilms Tum...

Unusual Clinical Presentation and Association of Cranial Dermoid Tumor and Tethered Cord Syndrome.

Tethered cord syndrome (TCS), a neurological disorder characterized by the lower settlement of the conus medullaris, is a congenital spinal disease which is caused by split cord syndrome, meningomyelo...

Medical and Biotech [MESH] Definitions

A syndrome resulting from cytotoxic therapy, occurring generally in aggressive, rapidly proliferating lymphoproliferative disorders. It is characterized by combinations of hyperuricemia, lactic acidosis, hyperkalemia, hyperphosphatemia and hypocalcemia.

A rare syndrome characterized by UROGENITAL ABNORMALITIES; GONADAL DYSGENESIS; PSEUDOHERMAPHRODITISM; and WILMS TUMOR. It is caused by a mutation in the Wilms tumor suppressor gene (GENES, WILMS TUMOR) on chromosome 11.

A syndrome characterized by CHRONIC KIDNEY FAILURE and GONADAL DYSGENESIS in phenotypic females with karyotype of 46,XY or 46,XX. It is caused by donor splice-site mutations of Wilms tumor suppressor gene (GENES, WILMS TUMOR) on chromosome 11.

A product of the lysis of plasminogen (profibrinolysin) by PLASMINOGEN activators. It is composed of two polypeptide chains, light (B) and heavy (A), with a molecular weight of 75,000. It is the major proteolytic enzyme involved in blood clot retraction or the lysis of fibrin and quickly inactivated by antiplasmins.

A contiguous gene syndrome associated with hemizygous deletions of chromosome region 11p13. The condition is marked by the combination of WILMS TUMOR; ANIRIDIA; GENITOURINARY ABNORMALITIES; and MENTAL RETARDATION.

More From BioPortfolio on "Elitek (Rasburicase) Immuno-Monitoring Study"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...


Searches Linking to this Trial